← Leaderboards
Sebastian G. Schneeweiss
Brigham And Women'S Hospital
$14,258,306
Attributed
$15,663,528
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,400,339 · 11
AHRQ$263,189 · 1
By mechanism
R01$8,712,567 · 5
U01$3,629,315 · 3
RC1$1,905,103 · 2
RC4$1,331,793 · 1
R03$84,750 · 1
Top collaborators
- Shirley Wang4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Daniel Hal Solomon$26,002,677
- Maurice Alan Brookhart$1,543,154
- William Shrank$650,213
- Til Sturmer$7,698,961
- Eunyoung Cho$2,679,152
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDatabasesBaseResearch PersonnelSafetyAlgorithmsDesignHealthcareRandomizedMonitorPhysiciansProgramsSubgroupPerformancePublicationsFutureMorbidity - Disease RateHealth Care Service UtilizationInnovationCostLeadPlacebosMedicaidData Sources
Grant awards (40)
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations$616,690
R01 · FY2025 · AR · contact PI
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations$636,546
R01 · FY2024 · AR · contact PI
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$713,351
R01 · FY2023 · HL
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations$656,232
R01 · FY2023 · AR · contact PI
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations$768,100
R01 · FY2022 · AR · contact PI
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$713,351
R01 · FY2022 · HL
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$691,871
R01 · FY2021 · HL
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$691,871
R01 · FY2020 · HL
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects$383,445
R01 · FY2012 · LM · contact PI
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects$389,385
R01 · FY2011 · LM · contact PI
Assessment of Treatment Effects in High-Dimensional, Routine Care Claims Data$1,331,793
RC4 · FY2010 · HL · contact PI
"Stopping Rules" for Drug Safety Monitoring Using Healthcare Databases$484,130
RC1 · FY2010 · LM · contact PI
Effectiveness studies with securely pooled healthcare data and adjusted analyses$450,614
RC1 · FY2010 · RR · contact PI
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects$417,999
R01 · FY2010 · LM · contact PI
Impact of Medicare Drug Coverage on Antidepressant Quality and Outcomes$393,750
U01 · FY2010 · MH · contact PI
"Stopping Rules" for Drug Safety Monitoring Using Healthcare Databases$490,456
RC1 · FY2009 · LM · contact PI
Effectiveness studies with securely pooled healthcare data and adjusted analyses$479,903
RC1 · FY2009 · RR · contact PI
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects$457,541
R01 · FY2009 · LM · contact PI
Impact of Medicare Drug Coverage on Antidepressant Quality and Outcomes$393,750
U01 · FY2009 · MH · contact PI
Antidepressant Use and Suicidality: Comparative Safety in Children and Adults$178,340
U01 · FY2009 · MH · contact PI
Antidepressant Use and Suicidality: Comparative Safety in Children and Adults$160,058
U01 · FY2009 · MH · contact PI
Impact of Medicare Drug Coverage on Antidepressant Quality and Outcomes$393,750
U01 · FY2008 · MH · contact PI
Antidepressant Use and Suicidality: Comparative Safety in Children and Adults$357,516
U01 · FY2008 · MH · contact PI
Impact of Medicare Drug Coverage on Antidepressant Quality and Outcomes$393,750
U01 · FY2007 · MH · contact PI
Antidepressant Use and Suicidality: Comparative Safety in Children and Adults$370,503
U01 · FY2007 · MH · contact PI
Remibursement Limits, Antidepressants, and Outcomes$258,356
U01 · FY2007 · MH · contact PI
Antidepressant Use and Suicidality: Comparative Safety in Children and Adults$387,450
U01 · FY2006 · MH · contact PI
Remibursement Limits, Antidepressants, and Outcomes$342,092
U01 · FY2006 · MH · contact PI
Effects of income-based drug charges on older Patients$266,072
R01 · FY2006 · AG · contact PI
Consequences of Drug Cost Sharing:A New Randomized Trial$263,189
R01 · FY2006 · HS · contact PI
Effects of income-based drug charges on older Patients$311,400
R01 · FY2005 · AG
Consequences of Drug Cost Sharing:A New Randomized Trial$0
R01 · FY2005 · HS
Effects of income-based drug charges on older Patients$350,325
R01 · FY2004 · AG
Consequences of Drug Cost Sharing:A New Randomized Trial$0
R01 · FY2004 · HS
Effects of income-based drug charges on older Patients$385,199
R01 · FY2003 · AG
Consequences of Drug Cost Sharing:A New Randomized Trial$0
R01 · FY2003 · HS
CONSEQUENCES OF DRUG COST SHARING IN THE ELDERLY$0
R01 · FY2002 · HS
Evaluating Drug Benefit Policy Changes in the Elderly$84,750
R03 · FY2001 · AG
CONSEQUENCES OF DRUG COST SHARING IN THE ELDERLY$0
R01 · FY2001 · HS
CONSEQUENCES OF DRUG COST SHARING IN THE ELDERLY$0
R01 · FY2000 · HS